Area of Interest: Out-Licensing
What we are looking for:
Our products may present an opportunity for you – through a licensing agreement in your market, a co-marketing arrangement, or another chance to collaborate.
Our tamper-resistant formulation technology INTAC® represents an innovative approach to address the issues of abuse of prescription drugs. This novel technology platform for immediate release (IR) and modified release (MR) formulations can also be used for various non-opioid drugs prone to abuse. For more information, please see www.intac.grunenthal.com
Read our recent press releases on Grünenthal Out-Licencing projects
-
Grünenthal GmbH exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership
-
Grünenthal GmbH granted its consent to the transfer of the license rights for Nucynta® (tapentadol) in the U.S. from Janssen Pharmaceuticals, Inc., to Depomed, Inc.
-
Grünenthal Announces Termination of License Agreement with Actavis for the Development of Cebranopadol as of October 1, 2014
